Condition: Cervical Cancer by FIGO Stage 2018 · Sponsor: Varian, a Siemens Healthineers Company
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
This description comes directly from the study's public registry record.
Heike Hausen, MD · 1-650-743-7400 · heike.hausen@varian.com
Sean Davidson, MS · sean.davidson@varian.com
Always discuss trial participation with your own doctor first.
| University of Alabama Birmingham | Burmingham, Alabama, United States | Recruiting |
| University of Arkansas Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| Moores Cancer Center at UC San Diego Health | La Jolla, California, United States | Recruiting |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Texas Southwestern | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05197881